

## **Completion of recruitment for a multi-center, randomized, controlled clinical study of Arthrosamid® for knee osteoarthritis**

**May 15, 2020:** Contura is pleased to announce that, in April 2020, it completed recruitment for a multi-centre, randomised, controlled, double-blinded clinical study of Arthrosamid in patients with knee osteoarthritis. The study enrolled 241 patients at three specialist treatment centres to compare the reduction in pain achieved at 3-months, 6-months and 12-months, following a single injection of Arthrosamid against the reduction in pain achieved with a major brand of hyaluronic acid, a common treatment for osteoarthritis of the knee.

Commenting on the study, Patrick Banks, Chief Executive of Contura said: "***The completion of recruitment for this study is a major milestone for Contura. Arthrosamid is the culmination of several years of hard work by the company to develop an effective and long-lasting treatment for knee osteoarthritis, a condition for which there is a significant unmet need. In 2018 we reported on the treatment of more than one hundred patients in an observational proof-of-concept study with Arthrosamid.<sup>1</sup> This was followed by a retrospective case series analysis into the safety of the product in 2019.<sup>2</sup> Then, in March of this year, we announced the regulatory approval for the sale of Arthrosamid in Europe, following the completion of the first three months of a 12-month prospective open label study which demonstrated a significant pain reduction in Arthrosamid treated patients. This current study seeks to further clarify the effectiveness of Arthrosamid in meeting the unmet needs of knee osteoarthritis patients by comparing Arthrosamid results with those achieved by a leading alternative product for the same indication and should report in mid-2021.***"

### **About Arthrosamid**

Arthrosamid is a polyacrylamide hydrogel developed by Contura as a long-lasting intra-articular injection for the treatment of osteoarthritis in humans. Development of Arthrosamid commenced after the generation of impressive clinical data with Arthramid Vet, a related product of the company, in the treatment of lameness in horses. Arthrosamid becomes embedded in the synovial membrane, providing increased cushioning and other therapeutic benefits to patients with knee osteoarthritis. Patients benefit from both pain relief and improved mobility.

### **About Osteoarthritis of the Knee**

Osteoarthritis is the most common form of arthritis, characterised by pain and physical disability. More than 10% of people over the age of 55 suffer from symptomatic osteoarthritis, primarily involving the knees. Due to the pivotal role of the knee in basic

mobility, knee osteoarthritis is associated with significant impairments and limitations in basic activities of daily living, such as walking and moving around, self-care and participation in activities, all contributing to a reduced quality of life. There is a shortage of effective treatments available for knee osteoarthritis today. Even the widely used hyaluronic acids are accepted to have limited efficacy and work for limited duration.

### **About Contura**

Contura is headquartered in London and has its manufacturing facility in Copenhagen, Denmark. It specialises in the distribution and sale of healthcare products, both pharmaceuticals and medical devices, focused primarily on women's health and pain. Its lead products are Bulkamid®, Arthrosamid®, Aquamid®, Regurin® XL and Cystistat®. Arthrosamid®, the Company's treatment for osteoarthritis of the knee, is the most recent addition to its suite of products and is due to be launched onto the European market in mid-2021. Contura has an established sales and marketing infrastructure in the leading European and worldwide markets. It has its own offices in the UK, United States, Denmark, Germany, France and Italy, currently employing around 55 staff worldwide.

### **References**

1. Henriksen et al. Intra-articular 2.5% polyacrylamide hydrogel for the treatment of knee osteoarthritis: an observational proof-of-concept cohort study. *Clinical and Experimental Rheumatology* 2018.
2. Overgaard et al. Safety of intra-articular polyacrylamide hydrogel for the treatment of knee osteoarthritis symptoms: a retrospective case series. *Clinical Orthopedics Advanced Research Journal: COARJ-100001*, Issue 1, 2019.

-ENDS-

### **Contact:**

For further information please contact the Contura Press Office (managed by Trinity PR) on +44 20 7112 4905 / +44 770 948 7959 / [jo.hudson@trinitypr.co.uk](mailto:jo.hudson@trinitypr.co.uk)

[www.contura.com](http://www.contura.com)